Transforming growth factor beta 1 (TGF β1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.
CONCLUSION: The present study indicates that TGFB1 variants have subtype-specific roles in BC and may switch from tumor suppressor to promoter during tumor development, consistent with TGFβ1 dual role in BC pathogenesis. PMID: 29362917 [PubMed - as supplied by publisher]
(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.
Conclusion: ICC using LBC can be a useful tool in assessing biomarkers in advanced cases of breast cancer where surgery is not possible or cases where ASCO/CAP guidelines for management are not followed.
This article summarizes the milestones in t he development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Blossom Lake, Donna Appleton, Abel Zachariah, Habib Khan, Kerry Flemming, Jennifer Neill, Laura Pettit
An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?
This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.
Conditions: HER2-positive Breast Cancer; Breast Cancer Metastatic Interventions: Drug: Palbociclib 75mg; Drug: Letrozole 2.5mg; Drug: T-DM1; Drug: Palbociclib 100mg; Drug: Palbociclib 125mg; Drug: Palbociclib Sponsors: University of Kansas Medical Center; Pfizer Not yet recruiting
On October 16, 2018, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),...
Conclusion: This study unveils a potential function of Gab2 in HER2-overexpressing breast cancer cells. Gab2 might be a potential target in the clinical therapy of HER2-overexpressing breast carcinoma.Cell Physiol Biochem 2018;50:52 –65
Authors: Petrou P Abstract INTRODUCTION: Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several sub-types of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a monoclonal antibody, has proved its safety and efficacy in this specific subtype, nevertheless its high cost urges for caution among payers. Areas covered: The scope of this study is to systematically search and critically assess the economic evaluation studies of trastuzum...